References
- DiazELevineHBSullivanMCUse of the Medication Event Monitoring System to estimate medication compliance in patients with schizophreniaJ Psychiatry Neurosci20012632532911590972
- MeijerWEBouvyMLHeerdinkERUrquhartJLeufkensHGSpontaneous lapses in dosing during chronic treatment with selective serotonin reuptake inhibitorsBr J Psychiatry200117951952211731355
- ThompsonCPevelerRCStephensonDMcKendrickJCompliance with antidepressant medication in the treatment of major depressive disorder in primary care: A randomized comparison of fluoxetine and a tricyclic antidepressantAm J Psychiatry200015733834310698807
- KruseWWeberEDynamics of drug regimen compliance – its assessment by microprocessor-based monitoringEur J Clin Pharmacol1990385615652373129
- UrquhartJRole of patient compliance in clinical pharmacokinetics. A review of recent researchClin Pharmacokinet1994272022157988102
- UrquhartJCompliance and clinical trialsLancet1991337122412251673762
- UrquhartJThe impact of compliance on drug developmentTransplant Proc19993139S10372043
- UrquhartJIntroduction to pharmionics: The vagaries of ambulatory patients adherence to prescribed drug dosing regimens and some of their clinical and economic consequencesMannRDAndrewsEBPharmacovigilance2nd edChichester, UKJohn Wiley & Sons Ltd2007
- UrquhartJBernardVTaxonomy of patient compliance-related events in drug trialsNational Cancer Institute Conference on Causal Inference2001 Aug 9–13Snowbird, UT, US
- VrijensBToussetERodeRBertzRMayerSUrquhartJSuccessful projection of the time course of drug concentration in plasma during a 1-year period from electronically compiled dosing-time data used as input to individually parameterized pharmacokinetic modelsJ Clin Pharmacol20054546146715778427
- VrijensBGrossRUrquhartJThe odds that clinically unrecognized poor or partial adherence confuses population pharmacokinetic/pharmacodynamic analysesBasic Clin Pharmacol Toxicol20059622522715733218
- FrankECassanoGBRucciPAddressing the challenges of a cross-national investigation: Lessons from the Pittsburgh-Pisa study of treatment-relevant phenotypes of unipolar depressionClin Trials2008525326118559415
- BealBSheinerLNONMEM user’s guide, Part ISan Francisco, CAUniversity of California at San Francisco1992
- SheinerLBRosenbergBMaratheVVEstimation of population characteristics of pharmacokinetic parameters from routine clinical dataJ Pharmacokinet Biopharm19775445479925881
- SogaardBMengelHRaoNLarsenFThe pharmacokinetics of escitalopram after oral and intravenous administration of single and multiple doses to healthy subjectsJ Clin Pharmacol2005451400140616291715
- GutierrezMMRosenbergJAbramowitzWAn evaluation of the potential for pharmacokinetic interaction between escitalopram and the cytochrome P450 3A4 inhibitor ritonavirClin Ther2003251200121012809966
- WeissteinEW Distance. From MathWorld – A WolframMathWorld Web Resource: http://mathworld.wolfram.com/Distance.html. Accessed Feb 2011.
- BrundageRCYongFHFentonTSpectorSAStarrSEFletcherCVIntrapatient variability of efavirenz concentrations as a predictor of virologic response to antiretroviral therapyAntimicrob Agents Chemother20044897998414982792